Amgen Inc. Prepares for Q1 2025 Earnings with Solid Expectations
Amgen Inc. (AMGN), headquartered in Thousand Oaks, California, has a market capitalization of $149.1 billion. The company is recognized for its advanced human therapeutics across several fields, such as oncology, cardiovascular health, inflammation, bone health, and nephrology. With its impressive product lineup, which includes prominent drugs like Enbrel, Prolia, Repatha, and Neulasta, Amgen continues to fuel its growth through innovative science, strategic acquisitions, and the development of biosimilars.
Upcoming Earnings Report
Amgen is scheduled to disclose its fiscal Q1 2025 earnings after the market closes on Thursday, May 1. Analysts anticipate that the company will report earnings of $4.15 per share, reflecting a 4.8% increase from $3.96 per share during the same quarter last year. The company has impressively outperformed Wall Street’s expectations in its last four quarters, with a notable 5.6% EPS beat in Q4 2024.
Long-term Financial Projection
Looking ahead to fiscal 2025, analysts predict that the leading biotech firm will post an EPS of $20.61, which would mark a 3.9% rise compared to $19.84 in fiscal 2024.
Stock Performance Analysis
Over the past 52 weeks, AMGN shares have gained 5%, slightly underperforming the S&P 500 Index’s ($SPX) 5.4% increase. In contrast, the stock has outpaced the Health Care Select Sector SPDR Fund’s (XLV) 2.1% decline during the same timeframe.
Following its Q4 2024 earnings report on February 4, shares of AMGN surged 6.5% due to an impressive earnings performance, with adjusted EPS reaching $5.31 and revenue totaling $9.1 billion—both figures surpassed analyst expectations. Year-over-year, EPS rose by 13%, while revenue increased by 11%, and the operating margin climbed to 26.5%. Amgen’s notable product performances, including a 45% year-over-year surge in Repatha sales to $606 million and $460 million from recently acquired Tepezza, have strengthened investor confidence.
Analyst Ratings and Price Target
The consensus rating for AMGN stock is cautiously optimistic, labeled a “Moderate Buy” overall. Among the 30 analysts covering the stock, there are 14 “Strong Buys,” one “Moderate Buy,” 12 “Holds,” one “Moderate Sell,” and two “Strong Sells.” The average price target set by analysts for AMGN is $321.73, indicating a possible upside of 16% from its current price.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data presented here are purely for informational purposes. For further details, please refer to the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
